Forbes May 30, 2024
Robert Hart


Nestlé is tapping into the lucrative weight loss drug market by catering to customers’ “shifting” nutritional needs, CEO Mark Schneider told CNBC on Thursday, an optimistic pivot from one of the industry’s biggest players in the face of dire early predictions suggesting wildly popular drugs like Ozempic, Mounjaro and Wegovy would take a bite out of the food industry.

Key Facts

Get Forbes Breaking News Text Alerts: We’re launching text message alerts so you’ll always know the biggest stories shaping the day’s headlines. Text “Alerts” to (201) 335-0739 or sign up here.

Crucial Quote

Schneider said new lines and offerings targeting GLP-1 drug users will be an “addition” to the food and drinks industry moving forward, rather than its...

Today's Sponsors


Today's Sponsor


Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Provider, Retailer
Is Generative AI The New Hero Of Your Consumer Products And Retail Business?
When the Disruptors are Disrupted: Why Retailers are Tapping Out
Stores sold in Kroger, Albertsons merger to keep pharmacy, healthcare services
Walmart continues to adopt gen AI, while still keeping humans in the loop
215: Why Walmart and other retailers are exiting primary care delivery and why it matters

Share This Article